Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Clinical Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mycology

Quality Control Limits for Broth Microdilution Susceptibility Tests of Ten Antifungal Agents

A. L. Barry, M. A. Pfaller, S. D. Brown, A. Espinel-Ingroff, M. A. Ghannoum, C. Knapp, R. P. Rennie, J. H. Rex, M. G. Rinaldi
A. L. Barry
The Clinical Microbiology Institute, Wilsonville, Oregon;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. A. Pfaller
University of Iowa College of Medicine, Iowa City, Iowa;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. D. Brown
The Clinical Microbiology Institute, Wilsonville, Oregon;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Espinel-Ingroff
Medical College of Virginia Commonwealth University, Richmond, Virginia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. A. Ghannoum
University Center Reference Laboratory for Medical Mycology, Cleveland, Ohio;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Knapp
Trek Diagnostic Systems, Inc., Westlake, Ohio;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. P. Rennie
National Center for Mycology, Edmonton, Alberta, Canada; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. H. Rex
University of Texas Health Sciences Center, Houston, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. G. Rinaldi
University of Texas Health Sciences Center, San Antonio, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JCM.38.9.3457-3459.2000
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Broth microdilution susceptibility tests of Candidaspecies have now been standardized by the National Committee for Clinical Laboratory Standards (NCCLS). An eight-laboratory collaborative study was carried out in order to document reproducibility of tests of Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258 by the NCCLS method. Replicate broth microdilution tests were used to define control limits for 24- and 48-h MICs of amphotericin B, flucytosine, fluconazole, voriconazole, ketoconazole, itraconazole, caspofungin (MK 0991), ravuconazole (BMS 207147), posaconazole (SCH 56592), and LY 303366.

A standard reference method for testing the susceptibility of yeasts to antifungal agents has now been defined by the National Committee for Clinical Laboratory Standards (NCCLS) (3). Initially, the test was performed in 12-by-75-mm plastic tubes, but a more convenient broth microdilution version of that test (2) has been added to the current NCCLS document (3). Both methods are carried out in RPMI 1640 broth with glutamine and a phenol red pH indicator and with 3-(N-morpholino)propanesulfonic acid (MOPS) buffer (0.165 mol/liter for pH 7.0). The inoculum is adjusted to achieve a final concentration of 0.5 × 103 to 2.5 × 103 CFU/ml. The MICs are determined after 48 h of incubation at 35°C. For tests of azoles and flucytosine, the MICs are defined as the lowest concentration with a prominent decrease (at least an 80% decrease) in turbidity but, for amphotericin B, the endpoint is complete inhibition of growth. Although the reference method requires a 48-h incubation period, there is some evidence that a 24-h incubation time might be more appropriate for tests of the azoles (8, 9).

Early studies with the NCCLS tube dilution method have been carried out to describe MIC limits for tests of five different antifungal agents (3, 6, 10) against two designated quality control strains (5): Candida parapsilosis ATCC 22019 andCandida krusei ATCC 6258. The current report describes the results of an eight-laboratory collaborative effort to select quality control limits for broth microdilution tests of 10 antifungal agents tested against the two control strains. Both 24- and 48-h test results were recorded since there are differences of opinion concerning the question of which incubation period is most clinically relevant.

The experimental design followed the guidelines that have been specified for antibacterial agents (4), but with appropriate modifications for testing yeasts. The NCCLS broth microdilution method (3) was strictly followed except that MICs were recorded at 24 h as well as the standard 48-h time point. Frozen microdilution panels were prepared by S. Killian (Trek Diagnostic Systems, Westlake, Ohio). The trays contained serial dilutions of the antifungal agents in three different lots of RPMI 1640 broths (Sigma lot 77H46141, Cellgrow lot 90022025, and Irvine Scientific lot 951370226B); all lots were supplemented with glutamine (Sigma lot 484H1013) and 0.165 mol of MOPS buffer (Sigma lot 56H57035) per liter. Each well contained 100 μl of a 2× concentration of the study agent. The range of concentrations of each drug was broad enough to ensure that the majority of MICs were on scale. After inoculation of the test panels with 100 μl of a standardized inoculum prepared in RPMI 1640 broth, the desired final concentration of drug was achieved. The participants were provided with frozen microdilution trays as well as samples of all three lots of broth for inoculum preparation. The microdilution trays were stored at −60°C or colder until needed. In addition to the two established control strains, a strain of C. albicans (ATCC 90028) was also studied, but the results are not shown here because MICs of most drugs were too variable to be of value for quality control purposes. Other strains of C. albicans are currently being considered for this use.

On 10 different working days, the participants prepared inocula of the control strains, adjusted to match the turbidity of a McFarland 0.5 standard, as determined with a spectrophotometer (7), and further diluted in each of the three lots of RPMI 1640 broths. Microdilution trays were allowed to thaw and then inoculated with a multichannel pipette, being certain to match the lot of broth in the test panel to the lot used to prepare the inoculum. Immediately after inoculation, randomly selected trays were mixed by gentle tapping, and then 10 μl was removed from the growth control well for determination of the actual inoculum density. Each participant performed at least one colony count on each of 10 test days. The eight participants reported 139 such determinations for each control strain. The inocula forC. parapsilosis ATCC 22019 ranged from 0.5 × 103 to 6.4 × 103 CFU/ml (mean, 1.8 × 103 CFU/ml), and for C. krusei ATCC 6258 the counts ranged from 0.2 × 103 to 2.5 × 103 CFU/ml (mean, 1.2 × 103 CFU/ml). Trays were incubated at 35°C, and MICs were recorded after 24 h and again after 48 h. MICs were defined as the highest concentration that showed a sharp decline in the density of growth.

Because of technical problems with the first batch of fluconazole trays, new trays were prepared for retesting. The same protocol was used except that dilutions of amphotericin B were included for control purposes since MIC control limits for amphotericin B were defined by the first series of tests. Data from one of the eight participants in this second series were excluded because amphotericin B MICs were too high. Fluconazole MIC limits were based on data from the seven remaining laboratories even though the excluded fluconazole data were within the proposed MIC limits.

There were no major differences (>2 dilutions) between lots of RPMI 1640 broths, nor were there consistent discrepancies between laboratories. For that reason the data were pooled for analysis. The overall distribution of MICs are displayed in Table1. There were 240 MICs for each drug-microorganism combination and for each incubation time. Fewer MICs were available for evaluating fluconazole in the second trial because data from one laboratory were excluded and because another participant reported only the 48-h MICs. Control limits were described as ranges which included one doubling concentration on either side of the mode (1). When two adjacent concentrations displayed similar frequencies, the mode was assumed to be somewhere between the even log2 concentrations that were tested, and a four-dilution range was proposed (1). For most drugs, the 48-h MICs were approximately one doubling concentration greater than those recorded after 24 h. Every effort was made to select MIC ranges that included at least 95% of the recorded values and that occasionally required a four-dilution range around a clearcut mode.

View this table:
  • View inline
  • View popup
Table 1.

Distribution of MICs reported by eight participating facilities each testing two control strains on 10 separate days

Considering the nature of the endpoints that were being determined and the technical problems that needed careful attention, it was pleasing to see the degree of precision that was achieved when standard control strains were tested by the NCCLS microdilution method. Reproducibility with control strains was similar to that normally seen with antibacterial agents (1). On the other hand, our inability to achieve satisfactory precision with a reference strain of C. albicans is rather disturbing. Satisfactory results with the control strains do not guarantee accuracy with the clinical isolates being tested. Experience in determining MIC values and careful attention to procedural details are critically important when performing antifungal susceptibility tests.

With the quality control limits that we now propose (Table2), clinical or research laboratories will have a mechanism for assuring themselves that the antifungal microdilution test is being performed appropriately. The 24- and 48-h MIC limits that we propose (Table 2) have now been accepted by the NCCLS subcommittee on antifungal susceptibility tests and will appear in the next publication of that document.

View this table:
  • View inline
  • View popup
Table 2.

Proposed MIC ranges of various antifungal agents for two quality control strains of Candida spp. when tested by the NCCLS microdilution procedure

ACKNOWLEDGMENTS

This study was made possible by financial support from Pfizer Pharmaceuticals, New York, N.Y.; Schering Plough Research Institute, Kenilworth, N.J.; Merck Research Laboratory, Rahway, N.J.; Lilly Research Laboratories, Indianapolis, Ind.; Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Conn.; and the Janssen Research Foundation, Beerse, Belgium.

FOOTNOTES

    • Received 10 April 2000.
    • Accepted 13 June 2000.
  • Copyright © 2000 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Barry A. L.,
    2. Fuchs P. C.,
    3. Jones R. N.,
    4. the Collaborative Antimicrobial Susceptibility Testing Group
    Statistical criteria for selecting quality control limits for broth microdilution susceptibility tests with 39 different antimicrobial agents.Diagn. Microbiol. Infect. Dis.121989413420
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Espinel-Ingroff A.,
    2. Kish C. W. Jr.,
    3. Kerkering T. M.,
    4. Fromtling R. A.,
    5. Bartizal K.,
    6. Galgiani J. N.,
    7. Villareal K.,
    8. Pfaller M. A.,
    9. Gerarden T.,
    10. Rinaldi M. G.,
    11. Fothergill A.
    Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.J. Clin. Microbiol.30199231383145
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    National Committee for Clinical Laboratory Standards Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. 1997 National Committee for Clinical Laboratory Standards Wayne, Pa
  4. 4.↵
    National Committee for Clinical Laboratory Standards Development of in vitro susceptibility testing criteria and quality control parameters. Tentative standard M23-T3. 1998 National Committee for Clinical Laboratory Standards Wayne, Pa
  5. 5.↵
    1. Pfaller M. A.,
    2. Bale M.,
    3. Buschelman B.,
    4. Lancaster M.,
    5. Espinel-Ingroff A.,
    6. Rex J. H.,
    7. Rinaldi M. G.
    Selection of candidate quality control isolates and tentative control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods.J. Clin. Microbiol.32199416501653
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Pfaller M. A.,
    2. Bale M.,
    3. Buschelman B.,
    4. Lancaster M.,
    5. Espinel-Ingroff A.,
    6. Rex J. H.,
    7. Rinaldi M. G.,
    8. Cooper C. R.,
    9. McGinnis M. R.
    Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine.J. Clin. Microbiol.33199511041107
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Pfaller M. A.,
    2. Burmeister L.,
    3. Bartlett M. S.,
    4. Rinaldi M. G.
    Multicenter evaluation of four methods of yeast inoculum preparation.J. Clin. Microbiol.26198814371441
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Revankar S. G.,
    2. Kirkpatrick W. R.,
    3. McAtee R. K.,
    4. Fothergil A. W.,
    5. Redding S. W.,
    6. Rinaldi M. G.,
    7. Kilsenbeck S. G.,
    8. Patterson T. F.
    A randomized trial of continuous or intermittant therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: Clinical outcomes and development of fluconazole resistance.Am. J. Med.1051998711
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Rex J. H.,
    2. Kirkpatrick P. W.,
    3. Paetznick V. L.,
    4. Lozano-Chiu M.,
    5. Espinel-Ingroff A.,
    6. Anaissie E. J.
    Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis.Antimicrob. Agents Chemother.421998129134
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Rex J. H.,
    2. Pfaller M. A.,
    3. Lancaster M.,
    4. Odds F. C.,
    5. Bolstrom A.,
    6. Rinaldi M. G.
    Quality control guidelines for National Committee for Clinical Laboratory Standards—recommended broth macrodilution testing of ketoconazole and itraconazole.J. Clin. Microbiol.341996816817
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Quality Control Limits for Broth Microdilution Susceptibility Tests of Ten Antifungal Agents
A. L. Barry, M. A. Pfaller, S. D. Brown, A. Espinel-Ingroff, M. A. Ghannoum, C. Knapp, R. P. Rennie, J. H. Rex, M. G. Rinaldi
Journal of Clinical Microbiology Sep 2000, 38 (9) 3457-3459; DOI: 10.1128/JCM.38.9.3457-3459.2000

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Clinical Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Quality Control Limits for Broth Microdilution Susceptibility Tests of Ten Antifungal Agents
(Your Name) has forwarded a page to you from Journal of Clinical Microbiology
(Your Name) thought you would be interested in this article in Journal of Clinical Microbiology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Quality Control Limits for Broth Microdilution Susceptibility Tests of Ten Antifungal Agents
A. L. Barry, M. A. Pfaller, S. D. Brown, A. Espinel-Ingroff, M. A. Ghannoum, C. Knapp, R. P. Rennie, J. H. Rex, M. G. Rinaldi
Journal of Clinical Microbiology Sep 2000, 38 (9) 3457-3459; DOI: 10.1128/JCM.38.9.3457-3459.2000
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

antifungal agents
Candida
laboratories
Microbial Sensitivity Tests

Related Articles

Cited By...

About

  • About JCM
  • Editor in Chief
  • Board of Editors
  • Editor Conflicts of Interest
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Resources for Clinical Microbiologists
  • Ethics
  • Contact Us

Follow #JClinMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

 

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0095-1137; Online ISSN: 1098-660X